Literature DB >> 4507613

Inactivator of the third component of complement as an inhibitor in the properdin pathway.

C A Alper, F S Rosen, P J Lachmann.   

Abstract

Evidence has been obtained that a single protein, known to modulate classical complement activation, also acts as an inhibitor in the properdin or alternate complement pathway. A highly purified inactivator of the third component of complement (C3) from human serum inhibited the proteolysis of Factor B in the properdin system (glycine-rich beta-glycoprotein) by glycine-rich beta-glycoproteinase. The inhibition was by the enzymatic destruction of glycine-rich beta-glycoproteinase activity. The major fragment of C3, C3b, which is the only known substrate of the C3 inactivator, blocked the destruction of glycine-rich beta-glycoproteinase by the C3 inactivator. Thus, in its inhibition of the porperdin pathway, the C3 inactivator destroys both the active form of glycine-rich beta-glycoproteinase and a protein involved in the conversion of the zymogen form of this enzyme (proglycine-rich beta-glycoproteinase) to its active form. The increased susceptibility to infections in a patient homozygous for deficiency of the C3 inactivator demonstrates the biologic significance of this protein.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4507613      PMCID: PMC389672          DOI: 10.1073/pnas.69.10.2910

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

2.  Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3).

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

3.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

4.  Isolation and properties of a glycine-rich beta-glycoprotein of human serum.

Authors:  T Boenisch; C A Alper
Journal:  Biochim Biophys Acta       Date:  1970-12-22

5.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

6.  Deficiency of C3 inactivator in man.

Authors:  N Abramson; C A Alper; P J Lachmann; F S Rosen; J H Jandl
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

7.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

8.  Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum.

Authors:  N Tamura; R A Nelson
Journal:  J Immunol       Date:  1967-09       Impact factor: 5.422

9.  Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

10.  Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors:  C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  34 in total

1.  Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family.

Authors:  A S Grumach; M F Leitão; V G Arruk; M Kirschfink; A Condino-Neto
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Immune complexes in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

3.  Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay.

Authors:  B McLeod; P Baker; H Gewurz
Journal:  Immunology       Date:  1974-06       Impact factor: 7.397

4.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

5.  Genetic polymorphism of human factor I (C3b inactivator).

Authors:  S Nakamura; K Abe
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  The molecular basis of hereditary complement factor I deficiency.

Authors:  T J Vyse; B J Morley; I Bartok; E L Theodoridis; K A Davies; A D Webster; M J Walport
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

Review 7.  Genetics of the complement system.

Authors:  P Lachmann
Journal:  J Med Genet       Date:  1975-12       Impact factor: 6.318

8.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

9.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

10.  The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.

Authors:  P J Lachmann; L Halbwachs
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.